Tumour epithelial states of hepatocellular carcinoma: preserved lineage-factor RNAs, reduced hepatic output and genotype-linked markers beyond AFP and GPC3

This study characterizes individual genes and gene patterns in the malignant epithelium of primary intrahepatic hepatocellular carcinoma (HCC), asking which hepatic functions persist, which are lost, and which products complement alpha-fetoprotein (AFP) and glypican-3 (GPC3). It is a retrospective analysis of public datasets, with tumour thrombus and metastatic specimens excluded from the epithelial study population. The analysis integrates directly observed malignant cells from 24 donor units across three single-cell cohorts, donor-level epithelial profiles from five whole-tissue cohorts, and class-by-grade models in 348 TCGA-LIHC tumours with 47 tumour-adjacent pairs. LIRI-JP (49 HCC), HEPTROMIC (228 HCC and 168 cirrhotic livers), copy number, somatic mutations and clinical serum AFP provide complementary evidence. Hepatic loss was layered rather than uniform. Selected lineage-factor RNAs were relatively preserved while sensing receptors, metabolic effectors and secreted or surface products fell, most deeply in Hoshida S1. In directly observed malignant cells, CAR (NR1I3) was 3.05 log2 lower than in same-donor hepatocytes while HNF4A and CEBPA RNA were relatively preserved. S2 retained secretory and glucose-handling expression despite losing core metabolism, and its template-associated gene set separated from proliferation. These findings connect molecular class and differentiation to distinct epithelial expression states. AFP and GPC3 RNA were both undetected in a donor median of 63% of malignant cells, with substantial sequencing-depth dependence. Complementary genes formed TP53-associated cancer-testis, beta-catenin-associated, NRF2-associated and copy-number-linked families. A cell-selected AKR1B10/SRM/CYP17A1/S100P combination covered a median 77% of AFP/GPC3-undetected malignant cells across 23 eligible units, versus 15% in normal-site hepatocyte reference units. Its exploratory tissue-RNA AUC for RNA-defined AFP/GPC3-low HCC versus cirrhosis was 0.91; the three members with published serum assays reached 0.88 in tissue RNA. These cohort-calibrated estimates motivate subsequent serum testing. Clinical serum AFP defined a separate patient group. Among 18 Edmondson-G1, Hoshida-S3, hepatic-dominant tumours with serum AFP below 20 ng/mL, GPC3 and PAGE4 together accounted for all ten tumours positive for a previously assembled 22-entry antigen set, including eight of 13 stage-I cases. PAGE4 added five tumours beyond GPC3. C1QTNF3 and NOTUM marked the same six tumours: four of five with an MC3 CTNNB1 mutation, one of 12 without a recorded mutation, and one lacking MC3 data. The study provides a gene-level resource for investigating epithelial state and prioritizing complementary diagnostic and therapeutic candidates. The record includes the manuscript, supplementary methods and results, supplementary tables, figures and derived source data, including full effect tables and figure-level evidence. The findings support biological hypotheses for protein, circulating-marker and antigen-presentation studies. The manuscript and original contributions are shared under Creative Commons Attribution 4.0 International (CC BY 4.0). Third-party data and annotations retain their original licences and repository terms.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-17
DOI
https://doi.org/10.5281/zenodo.24298255
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Tumour epithelial states of hepatocellular carcinoma: preserved lineage-factor RNAs, reduced hepatic output and genotype-linked markers beyond AFP and GPC3

Young Min Park
1 links
Zenodo (CERN European Organization for Nuclear Research)
Hepatocellular Carcinoma Treatment and Prognosis
preprint

Tumour epithelial states of hepatocellular carcinoma: preserved lineage-factor RNAs, reduced hepatic output and genotype-linked markers beyond AFP and GPC3

Young Min Park
preprint en

Abstract

This study characterizes individual genes and gene patterns in the malignant epithelium of primary intrahepatic hepatocellular carcinoma (HCC), asking which hepatic functions persist, which are lost, and which products complement alpha-fetoprotein (AFP) and glypican-3 (GPC3). It is a retrospective analysis of public datasets, with tumour thrombus and metastatic specimens excluded from the epithelial study population. The analysis integrates directly observed malignant cells from 24 donor units across three single-cell cohorts, donor-level epithelial profiles from five whole-tissue cohorts, and class-by-grade models in 348 TCGA-LIHC tumours with 47 tumour-adjacent pairs. LIRI-JP (49 HCC), HEPTROMIC (228 HCC and 168 cirrhotic livers), copy number, somatic mutations and clinical serum AFP provide complementary evidence. Hepatic loss was layered rather than uniform. Selected lineage-factor RNAs were relatively preserved while sensing receptors, metabolic effectors and secreted or surface products fell, most deeply in Hoshida S1. In directly observed malignant cells, CAR (NR1I3) was 3.05 log2 lower than in same-donor hepatocytes while HNF4A and CEBPA RNA were relatively preserved. S2 retained secretory and glucose-handling expression despite losing core metabolism, and its template-associated gene set separated from proliferation. These findings connect molecular class and differentiation to distinct epithelial expression states. AFP and GPC3 RNA were both undetected in a donor median of 63% of malignant cells, with substantial sequencing-depth dependence. Complementary genes formed TP53-associated cancer-testis, beta-catenin-associated, NRF2-associated and copy-number-linked families. A cell-selected AKR1B10/SRM/CYP17A1/S100P combination covered a median 77% of AFP/GPC3-undetected malignant cells across 23 eligible units, versus 15% in normal-site hepatocyte reference units. Its exploratory tissue-RNA AUC for RNA-defined AFP/GPC3-low HCC versus cirrhosis was 0.91; the three members with published serum assays reached 0.88 in tissue RNA. These cohort-calibrated estimates motivate subsequent serum testing. Clinical serum AFP defined a separate patient group. Among 18 Edmondson-G1, Hoshida-S3, hepatic-dominant tumours with serum AFP below 20 ng/mL, GPC3 and PAGE4 together accounted for all ten tumours positive for a previously assembled 22-entry antigen set, including eight of 13 stage-I cases. PAGE4 added five tumours beyond GPC3. C1QTNF3 and NOTUM marked the same six tumours: four of five with an MC3 CTNNB1 mutation, one of 12 without a recorded mutation, and one lacking MC3 data. The study provides a gene-level resource for investigating epithelial state and prioritizing complementary diagnostic and therapeutic candidates. The record includes the manuscript, supplementary methods and results, supplementary tables, figures and derived source data, including full effect tables and figure-level evidence. The findings support biological hypotheses for protein, circulating-marker and antigen-presentation studies. The manuscript and original contributions are shared under Creative Commons Attribution 4.0 International (CC BY 4.0). Third-party data and annotations retain their original licences and repository terms.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Hepatocellular Carcinoma Treatment and Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon